Fig. 4From: XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)Regional access to burosumab in Europe for people living with XLH†. A Children with XLH (0–17 years old). B Adults with XLH (18+ years old). †As of March 2023Back to article page